Related Experiment Video
Updated: Dec 23, 2025
06:39
Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
Published on: February 18, 2020
7.1K
The Ultimaster coronary stent system: 5-year worldwide experience
Elisa Gherbesi1, Gian Battista Danzi2
1Department of Cardiology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milano, Italy.
Future Cardiology
|April 25, 2020
Summary
Newer drug-eluting stents, like the Ultimaster™/Ultimaster™ Tansei™ sirolimus-eluting stent, improve percutaneous coronary intervention outcomes. Real-world evidence confirms their excellent performance across diverse patient groups.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
Background:
- Contemporary drug-eluting stents (DES) offer improved outcomes over first-generation devices.
- Advancements include thinner struts and biocompatible polymers, reducing inflammation and promoting endothelialization.
Purpose of the Study:
- To analytically review clinical data on the Ultimaster™/Ultimaster™ Tansei™ sirolimus-eluting stent.
- To focus on real-world evidence demonstrating the device's performance.
Main Methods:
- Systematic review of controlled randomized studies and observational registries.
- Analysis of clinical data focusing on real-world evidence.
Main Results:
- The Ultimaster™/Ultimaster™ Tansei™ stent, a biodegradable polymer sirolimus-eluting stent, received CE mark approval in 2014/2018.
- Intense clinical evaluation has been conducted through randomized trials and registries.
- Real-world evidence indicates excellent performance in all clinical subsets.
Conclusions:
- The Ultimaster™/Ultimaster™ Tansei™ coronary stent system demonstrates excellent clinical performance.
- Latest real-world data supports its efficacy in diverse patient populations undergoing percutaneous coronary intervention.
